Journal of Medical Case Reports and Reviews

an Open Access Publication

STEREOTACTIC BODY RADIOTHERAPY (SBRT): CHANGING TRENDS IN THE MANAGEMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

VIRENDER SUHAG
COMMAND HOSPITAL PUNE
PROF SUNITA BS
Bio
PANKAJ VATS
Bio
TEJAS PANDYA
Bio
NISHANT LOHIA
Bio
VK SINGH
Bio
MANU TIWARI
Bio
  • Articles
  • Submited: January 22, 2019
  • Published: January 28, 2019

Abstract

Hepatocellular carcinoma (HCC) is considered as an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location or due to underlying poor liver function because HCC almost always develop in chronically inflamed livers. Depending on the extent of disease and comorbidities, multiple liver-directed therapy (LDT) options exist for the treatment of HCC. Historically, the use of external-beam radiotherapy (EBRT) for HCC been limited by toxicity to the uninvolved liver and surrounding structures. Advances in RT have improved dose conformality to the tumor and facilitated dose escalation, a key contributor to improved HCC radiation treatment outcomes. These advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy (SBRT)  as a promising LDT, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. This review will enlighten the primary physicians and oncology care providers about the promising and evolving role of RT in various stages of HCC.

How to Cite
SUHAG, V., BS, P., VATS, P., PANDYA, T., LOHIA, N., SINGH, V., & TIWARI, M. (2019). STEREOTACTIC BODY RADIOTHERAPY (SBRT): CHANGING TRENDS IN THE MANAGEMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC). Jmcrr, 2(2). Retrieved from http://jmcrr.info/index.php/jmcrr/article/view/34
Article reviewers

Journal Abstracting and Indexing

  • Orcid
  • CrossRef
  • NML
  • DOAJ
  • Clarivate